Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Immune system diseases

2

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

inflammatory response

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2017

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

EPA CompTox

2

FDA UNII

2

PUBCHEM

2

ChEMBL

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

CORTICOSTEROIDS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Glucocorticoids

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

21-DESACETYLDEFLAZACORT

T1LWN33J2P

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

inflammatory response

Conditions:

Immune system diseases

Deflazacort is a glucocorticoid developed for the treatment of different inflammatory and immune conditions. The drug is rapidly metabolized to an active metabolite, 21-hydroxy-deflazaxort that may cross the blood brain barrier. Deflazacort acts by s...

uppressing inflammatory response.

DEFLAZACORT

KR5YZ6AE4B

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 2017

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

inflammatory response

Conditions:

Immune system diseases

Deflazacort is a glucocorticoid developed for the treatment of different inflammatory and immune conditions. The drug is rapidly metabolized to an active metabolite, 21-hydroxy-deflazaxort that may cross the blood brain barrier. Deflazacort acts by s...

uppressing inflammatory response.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1